Celularity (CELU) AI Stock Analysis

• Market Cap: $59.63M
• Dividend Yield: N/A
• Average Volume (3M): 70.87K
• Price to Earnings (P/E): ―
• Beta (1Y): 3.85
• Revenue Growth: 138.11%
• EPS Growth: 76.60%
• Country: US
• Employees: 120
• Sector: Healthcare
• Sector Strength: 42
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 23,949,228
• 10 Day Avg. Volume: 139,155
• 30 Day Avg. Volume: 70,869
• PEG Ratio: -0.02
• Price to Book (P/B): 2.25
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -3.24
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 45 Neutral
• Price Target: $2.00 ▼( -19.68% Downside)

Celularity's stock score is primarily impacted by its financial performance, characterized by strong revenue growth but ongoing profitability challenges and high leverage. Technical analysis indicates a positive short-term momentum, but the stock is below key long-term moving averages. The valuation is impacted by negative earnings and no dividend yield.

Celularity Business Overview & Revenue Model

Company Description

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy. It also sells and licenses products that are used in surgical and wound care markets, such as Biovance and Interfyl; collects stem cells from umbilical cords and placentas; and provides cells storage under the LifebankUSA brand. The company was incorporated in 2016 and is headquartered in Florham Park, New Jersey.

How the Company Makes Money

Celularity makes money through the development and commercialization of its proprietary allogeneic cellular therapies. The company's revenue model is primarily driven by the sale of its therapeutic products, which are developed through its placenta-derived cellular platform. Key revenue streams include partnerships with pharmaceutical companies, collaborations, and potential licensing agreements where Celularity provides access to its technology and products. The company may also receive funding from grants and institutional investors to support its research and development activities. Significant factors contributing to its earnings include advancements in its clinical trials, regulatory approvals, and the successful commercialization of its therapies.

Celularity Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
48.20M	22.77M	17.98M	21.34M	14.28M	21.15M
	Gross Profit
30.95M	6.75M	-1.69M	11.68M	9.35M	14.82M
	EBIT
-15.76M	-192.29M	-25.60M	-148.01M	-78.09M	-1.68M
	EBITDA
-41.73M	-183.95M	23.58M	-88.11M	-202.41M	-1.68M
	Net Income Common Stockholders
-35.05M	-196.29M	14.19M	-100.12M	-208.23M	5.88M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
13.97M	227.00K	13.97M	37.24M	54.31M	917.01K
	Total Assets
401.07M	143.89M	401.07M	414.13M	431.01M	291.61M
	Total Debt
65.59M	65.42M	65.59M	31.14M	30.64M	28.06M
	Net Debt
51.62M	65.19M	51.62M	-6.10M	-23.67M	27.14M
	Total Liabilities
202.16M	102.93M	202.16M	314.71M	962.41M	28.21M
	Stockholders Equity
198.90M	40.96M	198.90M	99.42M	-531.40M	263.39M
Cash Flow		Free Cash Flow
-13.02M	-42.73M	-143.11M	-116.30M	-91.03M	-32.67M
	Operating Cash Flow
-12.34M	-38.69M	-137.88M	-110.10M	-63.19M	-1.10M
	Investing Cash Flow
1.49M	-4.05M	-5.24M	-5.90M	-12.81M	-286.85M
	Financing Cash Flow
6.04M	24.09M	119.84M	98.56M	102.01M	288.84M

Celularity Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.49
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CELU, the sentiment is Positive. The current price of 2.49 is above the 20-day moving average (MA) of 1.84, above the 50-day MA of 1.73, and above the 200-day MA of 2.21, indicating a bullish trend. The MACD of 0.18 indicates Negative momentum. The RSI at 62.14 is Neutral, neither overbought nor oversold. The STOCH value of 79.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CELU.

Celularity Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RPTX	53 Neutral	$56.62M	―	-71.64%	―	-98.90%	-177.17%
Sector *	53 Neutral	$5.14B	3.03	-43.89%	2.83%	16.75%	-0.06%
STTK	50 Neutral	$47.90M	―	-71.90%	―	69.65%	27.98%
CELU	45 Neutral	$59.63M	―	-232.51%	―	138.11%	76.60%
LTRN	45 Neutral	$36.13M	―	-75.66%	―	―	-31.16%
GBIO	39 Underperform	$24.81M	―	-70.06%	―	146.47%	57.85%
FBLG	38 Underperform	$32.91M	―	-559.73%	―	―	―

Celularity Corporate Events

Celularity Extends Note Maturity with YA II PN

On May 20, 2025, Celularity Inc. entered into a letter agreement with YA II PN, Ltd. to extend the maturity date of a Convertible Promissory Note from May 12, 2025, to August 15, 2025. In exchange, Celularity issued 100,000 shares of restricted common stock to YA, which will have piggyback registration rights for resale in future registration statements filed by the company.